Hollow-core Optical Fiber Gas Lasers (HOFGLAS): a review [Invited]

International audienceThe development of hollow core photonic crystal fibers with low losses over a broad spectral region in the near IR enabled the demonstration of a novel laser type - Hollow-core Optical Fiber Gas Laser (HOFGLAS). The laser combines attractive features of fiber lasers such as compactness and long interaction length of pump and laser radiation with those of gas lasers such as the potential for high output power and narrow line width. This paper summarizes recent developments and describes the demonstration of C2H2 and HCN prototype lasers. Avenues to extend laser emission further into the IR are discussed

Ayurvedic management of cirrhotic ascites

Cirrhosis is the final stage of most of the chronic liver diseases and is most invariably complicated by portal hypertension resulting in ascites. A case of chronic liver disease with portal hypertension (cryptogenic cirrhosis), managed at Amrita School of Ayurveda is discussed in this paper. The clinical picture was that of an uncomplicated cirrhotic ascites. Snehapāna (therapeutic oral administration of lipids) followed by virecana (purgation) was done after an initial course of nityavirecana (daily purgation). Later Vardhamāna pippalī rasāyana [administration of single drug - pippalī (piper longum) in a structured dose pattern] was administered with an intention of rejuvenating liver cells. Ascites and lower limb oedema were completely resolved after the therapy. No recurrence of ascites has been reported after a follow up period of one year

C2H2 gas laser inside hollow-core photonic crystal fiber based on population inversion

Lasing from population inversion is demonstrated from gas contained in a hollow-core kagome structured photonic crystal fiber. Laser pulses in the mid-IR (3.1-3.2 μm) were generated by optically pumping at λ ~ 1.5 μm

Mid-IR fiber lasers based on molecular gas-filled hollow-core photonic crystal fiber

Lasing from HCN gas contained in HC-PCF is observed for the first time. Mid-IR pulses (3.15 and 3.09 µm) were generated by optically pumping at 1.54 µm. A 12C2H2-filled gas laser is also studied quantitatively

Abstracts of the Cell Therapy Transplant Canada 2022 Annual Conference

On behalf of Cell Therapy Transplant Canada (CTTC), we are pleased to present the Abstracts of the CTTC 2022 Annual Conference. The conference was held in-person 15–18 June 2022, in Niagara Falls, Ontario. Poster authors presented their work during a lively and engaging welcome reception on Thursday, 16 June, and oral abstract authors were featured during the oral abstract session in the afternoon on Friday, 17 June 2022. Thirty-three (33) abstracts were selected for presentation as posters and six (6) as oral presentations. The top abstracts in each of four (4) categories, (1) Basic/Translational sciences, (2) Clinical Trials/Observations, (3) Laboratory/Quality, and (4) Pharmacy/Nursing/Other Transplant Support, received awards for both the oral and poster presentations. All of these were marked as “Award Recipient” with the relevant category. We congratulate all the presenters on their research and contribution to the field

Cell Therapy Transplant Canada (CTTC) Consensus-Based Guideline 2024 for Management and Treatment of Chronic Graft-Versus-Host Disease and Future Directions for Development

This is a consensus-based Canadian guideline whose primary purpose is to standardize and facilitate the management of chronic graft-versus-host disease (cGvHD) across the country. Creating uniform healthcare guidance in Canada is a challenge for a number of reasons including the differences in healthcare authority structure, funding and access to healthcare resources between provinces and territories, as well as the geographic size. These differences can lead to variable and unequal access to effective therapies for GvHD. This document will provide comprehensive and practical guidance that can be applied across Canada by healthcare professionals caring for patients with cGvHD. Hopefully, this guideline, based on input from GvHD treaters across the country, will aid in standardizing cGvHD care and facilitate access to much-needed novel therapies. This consensus paper aims to discuss the optimal approach to the initial assessment of cGvHD, review the severity scoring and global grading system, discuss systemic and topical treatments, as well as supportive therapies, and propose a therapeutic algorithm for frontline and subsequent lines of cGvHD treatment in adults and pediatric patients. Finally, we will make suggestions about the future direction of cGvHD treatment development such as (1) a mode-of-action-based cGvHD drug selection, according to the pathogenesis of cGvHD, (2) a combination strategy with the introduction of newer targeted drugs, (3) a steroid-free regimen, particularly for front line therapy for cGvHD treatment, and (4) a pre-emptive approach which can prevent the progression of cGvHD in high-risk patients destined to develop severe and highly morbid forms of cGvHD.Other UBCNon UBCReviewedFacultyResearche